publication_number
stringclasses 10
values | input
stringclasses 10
values | instruction
stringclasses 1
value | output
stringclasses 10
values | extracted_data
stringclasses 8
values | generated_description
stringclasses 10
values | all_claims_joined
stringclasses 10
values | whole_output
stringclasses 10
values | new_figures
stringclasses 10
values | fig_map
stringclasses 10
values | remap_log
stringclasses 7
values |
|---|---|---|---|---|---|---|---|---|---|---|
US11707532
| "<invention_disclosure>\n**Invention Disclosure: Polynucleic Acid Molecules for the Treatment of Myo(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<detailed_description>\nDM1 is a rare, monogenic, autosomal dominant, repeat expansion disorder. <c(...TRUNCATED)
| "{\"equations\": {}, \"tables\": {\"EXTRACTED_TABLE_0\": \"COLUMNS: Column 1 || Column 2 || Column 3(...TRUNCATED)
| "<detailed_description>The present disclosure relates generally to polynucleic acid molecules and th(...TRUNCATED)
| "1. A method of treating muscular dystrophy in a subject comprising administering to the subject a t(...TRUNCATED)
| "<detailed_description>\nDM1 is a rare, monogenic, autosomal dominant, repeat expansion disorder. <c(...TRUNCATED)
| "\"Various aspects of the disclosure are set forth with particularity in the appended claims. A bett(...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_2}\", \"2\": \"{EXTRACTED_FIGURE_1}\", \"3\": \"{EXTRACTED_FIGURE_5}\",(...TRUNCATED)
| "{\"table_final_map\": {\"EXTRACTED_TABLE_0\": \"EXTRACTED_TABLE_6\", \"EXTRACTED_TABLE_1\": \"EXTRA(...TRUNCATED)
|
US11242376
| "<invention_disclosure>\nInvention Disclosure: T-Cell Receptor Fusion Proteins for Cancer Treatment\(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<cs c=1,18><detailed_description>Provided herein are compositions of matter and methods of use for (...TRUNCATED)
|
{"equations": {}, "tables": {}, "chemistry": {}}
| "<detailed_description>The present invention is directed to compositions and methods of use for T-ce(...TRUNCATED)
| "1. A recombinant nucleic acid encoding a T-cell receptor (TCR) fusion protein (TFP) comprising:\n(a(...TRUNCATED)
| "<cs c=1,18><detailed_description>Provided herein are compositions of matter and methods of use for (...TRUNCATED)
| "\"The novel features of the invention are set forth with particularity in the appended claims. A be(...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_10}\", \"3\": \"{EXTRACTED_FIGURE_12}\", \"4\": \"{EXTRACTED_FIGURE_13}(...TRUNCATED)
|
{"table_final_map": {}, "equation_final_map": {}}
|
US09540444
| "<invention_disclosure>\nInvention Disclosure: Monoclonal Antibodies Targeting TLR4/MD-2 Complex\n\n(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<cs c=1><detailed_description>The present invention provides monoclonal antibodies that neutralize (...TRUNCATED)
|
{"equations": {}, "tables": {}, "chemistry": {}}
| "<detailed_description>The present invention relates generally to monoclonal antibodies that recogni(...TRUNCATED)
| "1. An isolated antibody that binds a Toll-like receptor 4 (TLR4)/MD-2 complex, wherein the antibody(...TRUNCATED)
| "<cs c=1><detailed_description>The present invention provides monoclonal antibodies that neutralize (...TRUNCATED)
| "\"{EXTRACTED_FIGURE_27} is a graph depicting the binding of one monoclonal antibody of the inventio(...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_27}\", \"2\": \"{EXTRACTED_FIGURE_31}\", \"3\": \"{EXTRACTED_FIGURE_20}(...TRUNCATED)
|
{"table_final_map": {}, "equation_final_map": {}}
|
US11142573
| "<invention_disclosure>\nInvention Disclosure: Antibodies Targeting Human Notch3\n\nField of the Inv(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<cs c=1,17,26><detailed_description>The antibodies disclosed herein are based on the antigen bindin(...TRUNCATED)
| "{\"equations\": {}, \"tables\": {\"EXTRACTED_TABLE_0\": \"COLUMNS: Column 1 || Column 2 || Column 3(...TRUNCATED)
| "<detailed_description>The present invention provides anti-human Notch3 antibodies and antigen-bindi(...TRUNCATED)
| "1. An isolated antibody that binds human Notch3 comprising: (i) an immunoglobulin heavy chain varia(...TRUNCATED)
| "<cs c=1,17,26><detailed_description>The antibodies disclosed herein are based on the antigen bindin(...TRUNCATED)
| "\"The invention can be more completely understood with reference to the following drawings. {EXTRA(...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_3}\", \"2\": \"{EXTRACTED_FIGURE_13}\", \"3\": \"{EXTRACTED_FIGURE_7}\"(...TRUNCATED)
| "{\"table_final_map\": {\"EXTRACTED_TABLE_0\": \"EXTRACTED_TABLE_1\", \"EXTRACTED_TABLE_1\": \"EXTRA(...TRUNCATED)
|
US11370819
| "<invention_disclosure>\n**Invention Disclosure: Antibody-Cytokine Trap for Cancer Immunotherapy**\n(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<cs c=1,2><detailed_description>The current invention permits localized reduction in TGFβ in a tum(...TRUNCATED)
| "{\"equations\": {}, \"tables\": {\"EXTRACTED_TABLE_0\": \"COLUMNS: Column 1 || Column 2 || Column 3(...TRUNCATED)
| "<detailed_description>The invention is directed to a bifunctional protein designed to modulate the (...TRUNCATED)
| "1. A protein comprising: a) human Transforming Growth Factor β Receptor II (TGFβRII), or a fragme(...TRUNCATED)
| "<cs c=1,2><detailed_description>The current invention permits localized reduction in TGFβ in a tum(...TRUNCATED)
| "\"{EXTRACTED_FIGURE_1}A is a schematic drawing of an anti-PD-L1/TGFβ Trap molecule comprising one (...TRUNCATED)
| "{\"2\": \"{EXTRACTED_FIGURE_17}\", \"3\": \"{EXTRACTED_FIGURE_9}\", \"4\": \"{EXTRACTED_FIGURE_10}\(...TRUNCATED)
| "{\"table_final_map\": {\"EXTRACTED_TABLE_0\": \"EXTRACTED_TABLE_0\", \"EXTRACTED_TABLE_1\": \"EXTRA(...TRUNCATED)
|
US09828635
| "<invention_disclosure>\nInvention Disclosure: Methods and Compositions for Predicting Tumor Respons(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<cs c=1,4><detailed_description>Definitions\n\nAs used herein, “AV-203” means the humanized ant(...TRUNCATED)
| "{\"equations\": {}, \"tables\": {\"EXTRACTED_TABLE_0\": \"COLUMNS: Column 1 || Column 2 || Column 3(...TRUNCATED)
| "<detailed_description>The present invention relates to the field of oncology and personalized medic(...TRUNCATED)
| "1. A method of treating a tumor with an anti-ERBB3 antibody, the method comprising: administering t(...TRUNCATED)
| "<cs c=1,4><detailed_description>Definitions\n\nAs used herein, “AV-203” means the humanized ant(...TRUNCATED)
| "\"{EXTRACTED_FIGURE_3} is a schematic diagram showing the CDR_{H1} , CDR_{H2} , and CDR_{H3} sequen(...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_3}\", \"2\": \"{EXTRACTED_FIGURE_17}\", \"3\": \"{EXTRACTED_FIGURE_23}\(...TRUNCATED)
| "{\"table_final_map\": {\"EXTRACTED_TABLE_0\": \"EXTRACTED_TABLE_2\", \"EXTRACTED_TABLE_1\": \"EXTRA(...TRUNCATED)
|
US12269894
| "<invention_disclosure>\n**Invention Disclosure: Anti-Fibrin Antibodies**\n\n**Field of the Inventio(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<detailed_description>Definitions\n\nUnless otherwise defined, all terms of art, notations and othe(...TRUNCATED)
| "{\"equations\": {\"EXTRACTED_EQUATION_0\": \"% ID = \\\\frac{Uptake}{ Injected Dose } * 100 %\", \"(...TRUNCATED)
| "<detailed_description>Embodiments of the present invention relate generally to the field of immunol(...TRUNCATED)
| "1. An isolated antibody that binds human fibrin γC or fibrinogen γC domain, comprising: a. a vari(...TRUNCATED)
| "<detailed_description>Definitions\n\nUnless otherwise defined, all terms of art, notations and othe(...TRUNCATED)
| "\"These and other features, aspects, and advantages of the present invention will become better und(...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_23}\", \"2\": \"{EXTRACTED_FIGURE_19}\", \"3\": \"{EXTRACTED_FIGURE_6}\(...TRUNCATED)
| "{\"table_final_map\": {\"EXTRACTED_TABLE_0\": \"EXTRACTED_TABLE_12\", \"EXTRACTED_TABLE_1\": \"EXTR(...TRUNCATED)
|
US10077304
| "<invention_disclosure>\nInvention Disclosure: High Affinity Antibodies Targeting Frizzled Receptors(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<cs c=1,3><detailed_description>The present invention provides high affinity antibodies such as mon(...TRUNCATED)
|
{"equations": {}, "tables": {}, "chemistry": {}}
| "<detailed_description>The present disclosure relates to antibodies, such as monoclonal antibodies, (...TRUNCATED)
| "1. An isolated antibody or antigen-binding fragment thereof that binds to one or more Frizzled rece(...TRUNCATED)
| "<cs c=1,3><detailed_description>The present invention provides high affinity antibodies such as mon(...TRUNCATED)
| "\"FIGS. 1A and 1B are a series of illustrations depicting the heavy chain and light chain sequences(...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_6}\", \"3\": \"{EXTRACTED_FIGURE_15}\", \"5\": \"{EXTRACTED_FIGURE_17}\(...TRUNCATED)
|
{"table_final_map": {}, "equation_final_map": {}}
|
US12180282
| "<invention_disclosure>\nInvention Disclosure: Anti-PD-L1 Antibodies and Antigen-Binding Fragments\n(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<detailed_description>The following description of the disclosure is merely intended to illustrate (...TRUNCATED)
| "{\"equations\": {}, \"tables\": {\"EXTRACTED_TABLE_0\": \"COLUMNS: Column 1 || Column 2 || Column 3(...TRUNCATED)
| "<detailed_description>The present disclosure relates to anti-PD-L1 antibodies and antigen binding f(...TRUNCATED)
| "1. An isolated polynucleotide encoding for an anti-PD-L1 antibody or an antigen binding fragment th(...TRUNCATED)
| "<detailed_description>The following description of the disclosure is merely intended to illustrate (...TRUNCATED)
| "\"{EXTRACTED_FIGURE_8} presents the binding of fully human PD-L1 antibodies to PD-1 expressing CHO (...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_8}\", \"2\": \"{EXTRACTED_FIGURE_15}\", \"3\": \"{EXTRACTED_FIGURE_13}\(...TRUNCATED)
| "{\"table_final_map\": {\"EXTRACTED_TABLE_0\": \"EXTRACTED_TABLE_0\", \"EXTRACTED_TABLE_1\": \"EXTRA(...TRUNCATED)
|
US12281169
| "<invention_disclosure>\nInvention Disclosure: Antagonist Antibodies Targeting Human OX40\n\nField o(...TRUNCATED)
| "You are a patent attorney. You will receive an invention disclosure as input. An invention disclosu(...TRUNCATED)
| "<detailed_description>The present disclosure relates to antagonist antibodies and fragments thereof(...TRUNCATED)
| "{\"equations\": {}, \"tables\": {\"EXTRACTED_TABLE_0\": \"COLUMNS: Column 1 || Column 2 || Column 3(...TRUNCATED)
| "<detailed_description>The present disclosure relates to the generation of antibodies and fragments (...TRUNCATED)
| "1. An antagonistic antibody or fragment thereof that binds to human OX40, wherein said antibody or (...TRUNCATED)
| "<detailed_description>The present disclosure relates to antagonist antibodies and fragments thereof(...TRUNCATED)
| "\"{EXTRACTED_FIGURE_8} : (A) Direct-binding ELISA on immobilized recombinant human OX40-his. Bindin(...TRUNCATED)
| "{\"1\": \"{EXTRACTED_FIGURE_8}\", \"2\": \"{EXTRACTED_FIGURE_5}\", \"3\": \"{EXTRACTED_FIGURE_3}\",(...TRUNCATED)
| "{\"table_final_map\": {\"EXTRACTED_TABLE_0\": \"EXTRACTED_TABLE_7\", \"EXTRACTED_TABLE_1\": \"EXTRA(...TRUNCATED)
|
README.md exists but content is empty.
- Downloads last month
- 17